T1	p 90 123	healthy adults ?60 years of age .
T2	p 1674 1696	adults ?60 years old .
T3	i 326 347	zoster vaccine ( ZV )
T4	i 681 918	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay . Adverse experiences ( AEs ) were recorded on a standardized Vaccination Report Card .
T5	i 1304 1311	placebo
T6	i 1500 1507	placebo
T7	i 1567 1599	IFN-? ELISPOT and gpELISA assays
T8	o 6 48	Safety , tolerability , and immunogenicity
T9	o 681 860	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay . Adverse experiences ( AEs )
T10	o 927 1007	No serious vaccine-related AEs occurred . VZV IFN-? ELISPOT geometric mean count
T11	o 1356 1377	peak ELISPOT response
T12	o 1421 1459	gpELISA geometric mean titers ( GMTs )
T13	o 1567 1599	IFN-? ELISPOT and gpELISA assays